Clinical Trial Update: Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated how hepatic impairment affects the pharmacokinetics of miricorilant in Non-alcoholic Steatohepatitis (NASH). The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Status: COMPLETED